Debra Patt, MD, PhD, MBA, MPH, discusses how AI can streamline prior authorization and revenue cycle workflows in community ...

Objectives: To quantify community care consultations for patients with newly diagnosed diabetic foot ulcers (DFUs), identify associated patient- and facility-level chara ...

The rapid expansion of cell and gene therapies and other very high-cost drugs may give value-based contracting a second life, ...

Advanced primary care may be one of employers' strongest tools for catching cancer earlier, and better support during and ...

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care. Patients receiving injectable glucagon-like peptide-1 receptor agonist (GLP-1 ...

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Safety-net claims emphasize disproportionate Medicaid and uncompensated care borne by 340B hospitals, whereas other analyses ...

AJMC: The release notes that sustaining progress "may depend on access to early cancer detection, timely diagnosis, and state-of-the-art treatment." Beyond smoking reduction, which of those access ...

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the ...

Adaolisa Anaka, PharmD, BCACP, AAHIVP, discusses a pharmacist-led model that targets access barriers to GLP-1 obesity therapy. Glucagon-like peptide-1 (GLP-1) receptor agonists have become a key ...

Prior authorization remains the dominant friction point, with nearly universal reporting of delays that widen the gap between ...